Preformed Antibodies Detected by Cytotoxic Assay or Multibead Array Decrease Liver Allograft Survival: Role of Human Leukocyte Antigen Compatibility
- 26 March 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (4) , 554-562
Abstract
The significance of human leukocyte antigen (HLA) compatibility and preformed antibodies in liver transplantation remains unclear. The objectives of this study were to evaluate, in a single-center cohort comprising 896 liver transplants, whether the degree of donor-recipient compatibility and preformed antibodies modified graft survival. Univariate Kaplan-Meier analysis demonstrated that donor-recipient HLA compatibility had a marginal impact on allograft survival. As for compatibility at individual antigen loci, 2 mismatches at HLA-A conferred a survival advantage in retransplanted allografts ( P = 0.011). HLA-B and HLA-DR loci did not play a significant role in outcome in any pathology. The concordance of results on preformed antibodies detected by complement-dependent cytotoxicity (CDC) and a multiple bead assay (Luminex® xMAP) showed a strong correlation between both techniques ( P < 0.0001). Both CDC-detected and Luminex-detected antibodies were associated with shorter graft survival within the first year post-transplant ( P = 0.01 and P = 0.016, respectively). Positive CDC T crossmatches and Luminex-detected HLA class II antibodies played a significant role in decreasing graft survival ( P = 0.043 and P = 0.0019 at 1 year, respectively, and P = 0.005 and P = 0.038 at 5 years, respectively). A correlation was also observed between the presence of preformed Luminex-detected class II or Luminex I and II antibodies and allograft rejection ( P = 0.001 and P = 0.042, respectively). In conclusion, although HLA typing is not a prerequisite for transplantation, screening of HLA antibodies with Luminex techniques and CDC crossmatch may be useful in the detection of at-risk patients that could benefit from increased surveillance and tailored therapy following transplantation. Liver Transpl, 2008. © 2008 AASLD.Keywords
This publication has 45 references indexed in Scilit:
- The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: An analysis of the OPTN databaseLiver Transplantation, 2006
- Impact of human leukocyte antigen matching in liver transplantationTransplantation, 2003
- Liver transplantationJournal of Hepatology, 2000
- IgG DONOR-SPECIFIC CROSSMATCHES ARE NOT ASSOCIATED WITH GRAFT REJECTION OR POOR GRAFT SURVIVAL AFTER LIVER TRANSPLANTATIONTransplantation, 1995
- HLA COMPATIBILITY AND LIVER TRANSPLANT OUTCOME Improved Patient Survival by HLA and Cross-MatchingTransplantation, 1994
- The need for a consensus agreement on indications of liver transplantationHepatology, 1994
- The Influence of HLA Compatibility on Graft Survival after Heart TransplantationNew England Journal of Medicine, 1994
- Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodiesTransplant Immunology, 1994
- THE LACK OF LONG-TERM DETRIMENTAL EFFECTS ON LIVER ALLOGRAFTS CAUSED BY DONOR-SPECIFIC ANTI-HLA ANTIBODIESTransplantation, 1993
- Benefits of HLA-A and HLA-B Matching on Graft and Patient Outcome after Cadaveric-Donor Renal TransplantationNew England Journal of Medicine, 1984